ST. PAUL, Minn., Aug. 28, 2017 /PRNewswire/ -- EnteroMedics
Inc. (NASDAQ:ETRM), a developer of minimally invasive medical
devices to treat obesity, metabolic diseases and other
gastrointestinal disorders, today announced that a
cost-effectiveness study analyzing vBloc Therapy for the treatment
of obesity was published in the American Journal of Managed Care on
August 25, 2017.
The study concludes that vBloc Therapy for Class II and III
obese patients with diabetes and Class III obese patients without
diabetes is likely to be a cost-effective alternative to
conventional weight loss therapy and that vagal nerve blocking
represents good value for the money from the perspective of a U.S.
payer.
Details of the study include:
- Analysis was conducted on individuals who have not been
successful with behavioral therapy or pharmacotherapy and who are
seeking a weight loss alternative that is cost-effective, minimally
invasive, and demonstrates favorable comparative safety
- Model design incorporated both BMI class stratification and
diabetes remission, as well as simulated cost and quality-adjusted
life-year outcomes
- Incremental cost effectiveness ratios (ICER) demonstrated vagal
nerve blocking therapy to be cost-effective relative to
conventional therapy
"Demonstrating health economics and financial benefits with
vBloc therapy is imperative for prospective payers as they consider
coverage decisions," said Dan
Gladney, Chairman, President and Chief Executive Officer of
EnteroMedics. "This publication brings us one step closer to
increasing the accessibility to vBloc for the thousands of
individuals who are seeking vBloc as a solution for obesity and
associated comorbidities, but for whom the cost of the technology
is prohibitive."
The study was led by Boston Health Economics in Waltham, Massachusetts. The full online
publication can be accessed by visiting:
http://www.ajmc.com/journals/issue/2017/2017-vol23-n8/Cost-Effectiveness-Analysis-of-Vagal-Nerve-Blocking-for-Morbid-Obesity.
About vBloc® Therapy
vBloc Therapy works to control sensations of hunger using a
pacemaker-like device that is implanted under the skin during a
safe, minimally invasive procedure that does not alter or remove
any patient anatomy. The vBloc System is designed to give the
patient a sensation of fullness, empowering them to eat less,
control their appetite, and lose weight. Studies have shown that
vBloc Therapy produces meaningful weight loss while also reducing
comorbidity factors related to obesity.
vBloc Therapy is approved for use in people aged 18 years and
older who are obese, with a BMI of 40 to 45 kg/m2, or a BMI of 35
to 39.9 kg/m2 with a related health condition such as Type 2
diabetes, high blood pressure, high cholesterol levels or
obstructive sleep apnea who have had a poor response to trying to
lose weight under supervision in the last 5 years.
About EnteroMedics Inc.
EnteroMedics is a medical device company focused on the
development and commercialization of technology to treat obesity
and metabolic diseases. vBloc® Neurometabolic Therapy, delivered by
an FDA-approved pacemaker-like device called the vBloc® System, is
designed to help patients feel full and eat less by intermittently
blocking hunger signals on the vagus nerve. EnteroMedics recently
acquired the Gastric Vest System™ through its acquisition of
BarioSurg, Inc.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These forward-looking statements generally can be identified
by the use of words such as expect," "plan," "anticipate," "could,"
"may," "intend," "will," "continue," "future," other words of
similar meaning and the use of future dates. Forward-looking
statements in this release include statements regarding the
cost-effectiveness and value of vBloc Therapy and our goal of
increasing the accessibility to vBloc. These forward-looking
statements are based on the current expectations of our management
and involve known and unknown risks and uncertainties that may
cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others: our
limited history of operations; our losses since inception and for
the foreseeable future; our limited commercial sales experience
with our vBloc® System for the treatment of obesity in the United States or in any foreign market
other than Australia and the
European Community; the competitive industry in which we operate;
our ability to maintain compliance with the Nasdaq continued
listing requirements; our ability to commercialize our vBloc®
System; our dependence on third parties to initiate and perform our
clinical trials; the need to obtain regulatory approval for any
modifications to our vBloc® System; physician adoption of our
vBloc® System and vBloc® Neurometabolic Therapy; our ability to
obtain third party coding, coverage or payment levels; ongoing
regulatory compliance; our dependence on third party manufacturers
and suppliers; the successful development of our sales and
marketing capabilities; our ability to raise additional capital
when needed; international commercialization and operation; our
ability to attract and retain management and other personnel and to
manage our growth effectively; potential product liability claims;
the cost and management time of operating a public company;
potential healthcare fraud and abuse claims; healthcare legislative
reform; and our ability to obtain and maintain intellectual
property protection for our technology and products. These and
additional risks and uncertainties are described more fully in the
Company's filings with the Securities and Exchange Commission,
particularly those factors identified as "risk factors" in Exhibit
99.3 of our current report on Form 8-K filed July 26, 2017. We
are providing this information as of the date of this press release
and do not undertake any obligation to update any forward-looking
statements contained in this document as a result of new
information, future events or otherwise.
View original content with
multimedia:http://www.prnewswire.com/news-releases/study-concludes-vagal-nerve-blocking-with-enteromedics-vbloc-therapy-is-cost-effective-300510312.html
SOURCE EnteroMedics Inc.